"Radioimmunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).
| Descriptor ID |
D016499
|
| MeSH Number(s) |
E02.095.465.425.750 E02.186.750 E02.815.520
|
| Concept/Terms |
Radioimmunotherapy- Radioimmunotherapy
- Radioimmunotherapies
- Immunoradiotherapy
- Immunoradiotherapies
|
Below are MeSH descriptors whose meaning is more general than "Radioimmunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Radioimmunotherapy".
This graph shows the total number of publications written about "Radioimmunotherapy" by people in this website by year, and whether "Radioimmunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Radioimmunotherapy" by people in Profiles.
-
Current regimens and novel agents for mantle cell lymphoma. Br J Haematol. 2014 Oct; 167(1):3-18.
-
End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. Clin Cancer Res. 2013 Dec 01; 19(23):6566-77.
-
Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications. Leuk Lymphoma. 2010 Jul; 51(7):1163-77.
-
Experience with 90Y-ibritumomab tiuxetan for relapsed classical Hodgkin lymphoma. Ann Oncol. 2009 Jun; 20(6):1147-8.
-
Biokinetics of yttrium-90--labeled huBrE-3 monoclonal antibody. Cancer. 2002 Feb 15; 94(4 Suppl):1240-8.
-
Radioiodinated antibody targeting of the HER-2/neu oncoprotein. Nucl Med Biol. 1997 Jul; 24(5):451-9.
-
Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach. Semin Oncol. 1996 Dec; 23(6 Suppl 14):41-8.
-
High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial. Cancer Res. 1995 Dec 01; 55(23 Suppl):5921s-5924s.
-
Progress in radioimmunotherapy. N Engl J Med. 1993 Oct 21; 329(17):1266-8.
-
Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med. 1993 Sep; 34(9):1595-601.